RxDoctor Payments Data

Simon Starosta-Rubinstein, MD

Neurology · South Miami, FLNPI 1063647709

Payments from drug & device makers

$16,858in general payments, 2019–2025

Across 866 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • AbbVie$971
  • UCB, Inc.$833
  • Lilly USA, LLC$818
  • Biogen$712
  • plus $11K from 54 others

What the payments were for

  • Speaking & faculty fees$1901%
  • Food & beverage$15,76694%
  • Education$9025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.60$1,542
Neurocrine Biosciences, Inc.86$1,044
AbbVie(2 entities)57$971
UCB, Inc.40$833
Lilly USA, LLC41$818
Biogen35$712
Mallinckrodt Hospital Products Inc.24$655
Argenx US, Inc.27$599
Acadia Pharmaceuticals Inc33$592
Pfizer42$545
Eisai Inc.27$541
Amgen(2 entities)24$527
SK Life Science, Inc.23$521
Amneal Pharmaceuticals LLC23$508
Kyowa Kirin, Inc.24$411
AstraZeneca(2 entities)20$382
Adamas Pharmaceuticals, Inc.26$345
Acorda Therapeutics, Inc18$332
Lundbeck LLC14$320
EMD Serono, Inc.12$304
Almatica Pharma LLC12$295
Otsuka America Pharmaceutical, Inc.14$286
Johnson & Johnson(2 entities)9$270
Novartis11$233
Tanabe Pharma America, Inc.9$209
MDD US Operations, LLC9$198
Neurelis, Inc.9$170
TG Therapeutics, Inc.7$166
Biohaven Pharmaceuticals, Inc.8$165
E.r. Squibb & Sons, L.L.C.8$165
CSL Behring6$153
Sunovion Pharmaceuticals Inc.8$151
Upsher-smith Laboratories LLC7$135
Supernus Pharmaceuticals, Inc.9$135
Sanofi6$134
Merz Pharmaceuticals, LLC7$124
Avion Pharmaceuticals8$116
Takeda Pharmaceuticals U.S.A., Inc.5$114
Biohaven Pharmaceutical Holding Company Ltd.6$111
Cycle Pharmaceuticals Inc5$105
Bristol Myers Squibb5$104
Avanir Pharmaceuticals, Inc.6$100
Banner Life Sciences, LLC5$87
Axsome Therapeutics, Inc.3$80
ANI Pharmaceuticals, Inc.2$67
Corium, LLC4$66
Scilex Pharmaceuticals Inc.3$64
Alfasigma USA, Inc.2$38
Abbott2$38
Catalyst Pharmaceuticals, Inc.1$35
Akcea Therapeutics, Inc.2$33
Aquestive Therapeutics, Inc.1$22
Sobi, Inc1$22
Livanova USA, Inc.1$22
Philips North America LLC1$20
Boston Scientific1$19
Insightec,inc1$18
C2n Diagnostics, LLC1$17
Currax Pharmaceuticals LLC1$15
Aprecia Pharmaceuticals, LLC1$15

How this compares

$16,858 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$366,473
Medicare patients
321
Services billed
68,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate40$223,441
GocovriAmantadine Hcl32$140,617
RytaryCarbidopa/Levodopa104$108,502
CopaxoneGlatiramer Acetate11$59,850
AmpyraDalfampridine12$47,757
NeuproRotigotine40$37,935
OngentysOpicapone12$13,308
Carbidopa-LevodopaCarbidopa/Levodopa282$11,727
Memantine Hcl130$7,992
Rivastigmine37$6,891
Methazolamide19$5,273
Carbidopa-Levodopa ErCarbidopa/Levodopa108$3,830
AmantadineAmantadine Hcl47$3,674
Donepezil Hcl216$3,287
Gabapentin88$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$592$223,44140 claims
MDD US Operations, LLCGocovri$198$140,61732 claims
Amneal Pharmaceuticals LLCRytary$508$108,502104 claims
Teva Pharmaceuticals USA, Inc.Copaxone$1,542$59,85011 claims
Acorda Therapeutics, IncAmpyra$332$47,75712 claims
UCB, Inc.Neupro$833$37,93540 claims
Neurocrine Biosciences, Inc.Ongentys$1,044$13,30812 claims
Almatica Pharma LLCSertraline Hcl$295$55437 claims
Upsher-smith Laboratories LLCTopiramate$135$30914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →